MK-571 (sodium)

• UNSPSC Description:

  MK-571 (L-660711) sodium is an orally active, potent and selective competitive leukotriene D4 (LTD4) receptor antagonist, with Ki values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 sodium is also a inhibitor of multidrug resistance-associated protein MRP4 (ABCC4) and ABCC1 (MRP1). MK-571 sodium inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release[1][2][3].

• Target Antigen:

  Leukotriene Receptor; LPL Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/mk-571-sodium.html

• Purity:

  99.75

• Solubility:

  DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 12.5 mg/mL (ultrasonic)

• Smiles:

  O=C(O[Na])CCSC(C1=CC=CC(/C=C/C2=NC3=CC(Cl)=CC=C3C=C2)=C1)SCCC(N(C)C)=O

• Molecular Weight:

  537.07

• References & Citations:

  [1]Jones TR, et al. Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D₄ receptor antagonist. Can J Physiol Pharmacol. 1989 Jan;67(1):17-28.|[2]Hara Y, et al. Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. J Clin Invest. 2011 Jul;121(7):2888-97.|[3]Mitra P, et al. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16394-9.Arch Toxicol. 2020 Nov;94(11):3799-3817.|Biomed Pharmacother. 2018 Oct;106:1563-1569.|Brain Res Bull. 2022 Aug 15;S0361-9230(22)00199-X.|Cancer Res Commun. 2024 Apr 9;4(4):1024-1040.|Cell. 2023 Dec 7;186(25):5500-5516.e21.|CNS Neurosci Ther. 2022 Oct 17.|Commun Biol. 2024 May 23;7(1):621.|Eberhard Karls Universität Tübingen. 2022 Feb.|Eur J Drug Metab Pharmacokinet. 2022 Feb 3.|Eur J Drug Metab Pharmacokinet. 2024 Jul 4.|Eur J Pharm Sci. 2023 May 1.|Free Radic Biol Med. 2024 Jun 19:S0891-5849(24)00531-8.|Int J Nanomedicine. 2019 Nov 27;14:9217-9234.|J Appl Toxicol. 2024 Jul 18.|Pharmaceutics. 2024 May 29.|Pharmacol Res Perspect. 2022 Feb;10(1):e00928.|Regul Toxicol Phar. 2019 Nov;108:104449. |Toxicol Lett. 2020 Jul 1;327:9-18.|Xenobiotica. 2020 Mar;50(3):354-362. |Biomed Pharmacother. 2020 Sep;129:110506.|Cell Death Discov. 2024 Aug 14;10(1):364.|J Pharmaceut Biomed. 2020 Sep 10;189:113441.|Nat Commun. 2023 Sep 19;14(1):5709.|Viruses. 2019 Apr 24;11(4):378.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  115103-85-0